Prostate cancer can be classified into genomic subtypes, such as those with ETS-fusion gene arrangements and other subtypes that are negative for ETS-fusion gene arrangements, and either overexpress the SPINK1 oncogene or carry SPOP, FOXA1, or IDH1 mutations, or represent a triple-negative subtype (negative for ERG- and other ETS-fusions and SPINK1-negative) [6,41]. This evidence concerns the gene FOXA1 and prostate cancer.